The biotechnology firms space is changing, Sophie
But is your CRM data an asset or a liability in finding clients like Latigo Biotherapeutics and Aligos Therapeutics?
But is your CRM data an asset or a liability in finding clients like Latigo Biotherapeutics and Aligos Therapeutics?
Most CRMs are a mess — full of outdated, messy, and duplicated data.
We clean it up.
Using Clay, AI, and custom rules, we enrich your records with precision.
The result?
Smarter segmentation, faster lead routing, and a CRM your team can finally trust.
No more guesswork. Just clean, accurate data.
Only a handful of sales leaders are using automated CRM enrichment. But those who do are getting a serious edge.
To help you explore how it might support your workflow, here are a few questions:
1️⃣ How do you currently assess the completeness and readiness of the preclinical data you have for your key accounts? 2️⃣ In your experience, what are the most effective ways to identify key decision-makers within biotech firms when initiating contact? 3️⃣ What challenges have you faced in segmenting opportunities based on the specific needs and funding requirements of biotech clients?
If you’re ready for a CRM that works for you, not against you, let’s talk.
The form has been successfully submitted.